Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.710
+0.030 (1.79%)
May 13, 2026, 10:30 AM EDT - Market open

Traws Pharma Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Traws Pharma stock has a target of 8.00, which predicts a 367.84% increase from the current stock price of 1.71.

Price Target: $8.00 (+367.84%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$8.00$8.00$8.00$8.00
Change+367.84%+367.84%+367.84%+367.84%
* Price targets were last updated on Dec 3, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Traws Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingApr '26May '26
Strong Buy11
Buy00
Hold00
Sell00
Strong Sell00
Total11

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$8
Strong BuyInitiates$8+367.84%Dec 3, 2025

Financial Forecast

Revenue This Year
n/a
from 2.79M
Revenue Next Year
13.36M
EPS This Year
-2.67
from 0.83
EPS Next Year
-2.24
from -2.67
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
226.00K226.00K226.00K226.00K2.79M-13.36M
Revenue Growth
-2.17%---1,134.51%--
EPS
-24.01-22.75-22.57-35.210.83-2.67-2.24
EPS Growth
-------
Forward PE
-------
No. Analysts
-----44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027202820292030203120322033
Highn/a27.5M
Avgn/a13.4M
Lown/an/a

Revenue Growth

Revenue Growth20262027202820292030203120322033
High--
Avg--
Low--

EPS Forecast

EPS202620272028
High-2.42-1.35
Avg-2.67-2.24
Low-2.87-3.03

EPS Growth

EPS Growth202620272028
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.